98%
921
2 minutes
20
Demonstrating the feasibility of dose escalation for stereotactic recurrent head and neck (RHN) cancers with a HyperArc-based RapidPlan (HARP) model using custom Simultaneous Integrated Boost Injector (SIBI) through Eclipse Scripting API (ESAPI) to facilitate automated treatment planning. Five previously treated RHN patients prescribed 30 to 35 Gy in 3 or 5 fractions, four single-lesion and one two-lesion, were retrospectively replanned with HyperArc geometry on a TrueBeam LINAC (6MV-FFF) using a HARP model with SIBI to escalate tumor dose. Escalation was achieved through the GTV and a central hotspot optimization structure being pushed toward 130% and 140% the prescription dose, respectively. To accommodate this escalation, PTV coverage objectives were lessened. After dose calculation using AcurosXB, the stereotactic plan was normalized to the original plan's PTV D. On average, the mean dose to the PTVs and GTVs received an 11.5% ± 5.1% and 25.0% ± 8.7% increase. Maximum GTV dose increased by 39.5% ± 10.2% and GTV D increased by 16.4% ± 5.4%. Maximum dose to organs-at-risk (OARs) showed notable decreases for larynx (8.6 Gy), oral cavity (11.4 Gy), spinal cord (12.6 Gy), and parotids (11.4 Gy) for specific cases. Skin and brainstem saw maximum increases of 4.9 Gy and 3.4 Gy, respectively. Carotid artery dose was respected for all RHN plans, including plans with target overlap. All SIB plans were calculated automatically without user intervention in under 15 minutes on average. Patient-specific quality assurance results were clinically acceptable for RHN stereotactic radiotherapy delivery. Achieving an escalated stereotactic RHN dose without compromising nearby OARs has the potential to improve clinical outcomes through a possible increase in tumor local control while maintaining acceptable doses to OARs. Furthermore, the involvement of HyperArc, RapidPlan, and ESAPI allows for a standardized and streamlined clinical workflow, enabling resource-strained centers to deliver high-quality stereotactic RHN treatments without requiring extensive experience or time for manual planning.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.meddos.2025.07.005 | DOI Listing |
JAMA Psychiatry
September 2025
Denovo Biopharma LLC, San Diego, California.
Importance: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need.
Objective: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial.
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
J Oncol Pharm Pract
September 2025
Hematology/Oncology, Scripps Clinic, La Jolla, USA.
IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.
View Article and Find Full Text PDFEur J Clin Microbiol Infect Dis
September 2025
Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.
Purpose: This narrative review aims to provide an overview of current knowledge on mpox, emphasizing updated epidemiology and recent advances in treatment and prevention strategies, in light of the latest outbreaks.
Methods: We searched PubMed and Google Scholar for publications on 'Mpox' and 'Monkeypox' up to June 5, 2025. Grey literature from governmental and health agencies was also accessed for outbreak reports and guidelines where published evidence was unavailable.
Hormones (Athens)
September 2025
Division of Endocrinology, Baltimore VA Medical Center, Baltimore, MD, USA.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a fairly new class of agents for diabetes that have demonstrated significant benefits in glycemic control and cardiovascular outcomes with outpatient use. The aim of this review is to provide an overview of the effect of SGLT2i use on glycemic control and clinical outcomes in the hospital setting.An electronic search of PubMed was conducted to analyze publications that assessed the inpatient use of SGLT2i and included patients with diabetes.
View Article and Find Full Text PDF